Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

Stopped early · Phase 2

Conditions studied: Benign Prostatic Hyperplasia

In brief

The purpose of this trial is to evaluate the dose response relationship of lonidamine and the primary efficacy endpoint, International Prostate Symptom Score (IPSS), in subjects with symptomatic benign prostatic hyperplasia (BPH).

Key facts

Study ID

NCT00237536

Run by

Threshold Pharmaceuticals

People needed

240

Starts

2005-06-01

Expected to finish

2006-08-01

Last updated by the study team

2009-04-29

Who can join

Age: 65 and older, up to 80. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Capable of understanding the purpose and risks of the study and sign a statement of informed consent
• Male 65-80 years of age (or 40-80 with vasectomy). Vasectomized men must have documentation of azoospermia.
• Presence of LUTS (lower urinary tract symptoms) for at least 3 months
• Prostate volume measured by TRUS (transrectal ultrasound) > 30 cc
• Qmax < 15 mL/sec when measured by uroflowmetry (minimum of 125 mL must be voided)
• IPSS (International Prostate Symptom Score) > 12
• PSA > 1.0 ng/mL
• Must ensure and consent to use medically acceptable methods of contraception throughout the entire study with sexual partners of childbearing potential
• Able to comply with the prescribed treatment protocol and evaluations

You may not qualify if…

• Prior treatment for BPH with alpha blockers and/or herbal supplements for the treatment of BPH in the past 2 weeks (alpha-blockers and/or herbal supplements for the treatment of BPH are not allowed during the study). Prior treatment with 5-alpha reductase inhibitors is allowed if discontinued at least 3 months prior to enrollment.
• Prior surgery of the prostate (except biopsies; subject is eligible to enroll one month after full recovery from prostate biopsy.)
• Current or past evidence of malignant disease of the prostate or prostatic intraepithelial neoplasia (For subjects with PSA between 4 - 10 ng/mL, prostate cancer must be ruled out to the satisfaction of the Principal Investigator. Subjects with PSA >10 ng/mL are excluded).
• Active urinary tract infections (UTI)
• Active cardiac, renal or hepatic disease as evidenced by:
• Serum creatinine > 1.8 mg/dL
• ALT or AST > 2.5x the upper limit of normal
• History of active myocardial infarction, unstable cardiac arrhythmias, or stroke within 6 months prior to screening
• Uncontrolled congestive heart failure
• Uncontrolled diabetes mellitus (fasting blood glucose > 200 mg/dL)
• Use of systemic steroids for any reason (systemic steroid usage is not allowed during the study). Inhaled and/or topical steroids are allowed.
• Concurrent participation or participation in an investigational drug study within the past 30 days prior to screening
• Concomitant disease or condition that could interfere with the conduct of the study, or would in the opinion of the Investigator, pose an unacceptable risk to the subject

Where it is running

• Advanced Clinical Therapeutics — Tucson, Arizona, United States
• Chris B. Threatt, MD Inc. — Atherton, California, United States
• Urological Sciences Research Foundation — Culver City, California, United States
• Atlantic Urological Medical Group — Long Beach, California, United States
• California Professional Research — Newport Beach, California, United States
• San Diego Uro-Research — San Diego, California, United States
• Stanford University Hospital — Stanford, California, United States
• Urology Research Options — Aurora, Colorado, United States
• Connecticut Clinical Research Center Urology Specialists — Waterbury, Connecticut, United States
• South Florida Medical Research — Aventura, Florida, United States
• Tampa Bay Medical Research — Clearwater, Florida, United States
• Florida Healthcare Research — Ocala, Florida, United States
• Midwest Prostate & Urology Health Center — Chicago, Illinois, United States
• Specialty Care Research — Peoria, Illinois, United States
• Northeast Indiana research, LLC — Fort Wayne, Indiana, United States
• Metropolitan Urology — Jeffersonville, Indiana, United States
• Werner, Murdock & Francis, PA, Urology Associates — Greenbelt, Maryland, United States
• Sheldon J. Freedman, MD Ltd. — Las Vegas, Nevada, United States
• Delaware Valley Clinical Research — Cherry Hill, New Jersey, United States
• Lawrenceville Urology — Lawrenceville, New Jersey, United States
• Urology Healthcare Associates — Woodlane, New Jersey, United States
• Accumed Research Associates — Garden City, New York, United States
• New York University School of Medicine — New York, New York, United States
• Weill Medical College of Cornell University — New York, New York, United States
• Radiant Research. Columbus — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.